向CDK4/6通过破坏YAP1的稳定性来抑制结直肠癌
Yalei Wen1,2, Xiao Yang2, Shengrong Li1,2
1Research Institute for Maternal and Child Health, The Affiliated Guangdong Second Provincial General Hospital, Postdoctoral Research Station of Traditional Chinese Medicine, School of Pharmacy Jinan University Guangzhou China.
美国食品和药物管理局批准的药物Abemaciclib针对CDK4/6-DUB3途径降低YAP1,抑制结直肠癌 (CRC) 的进展. 这项研究揭示了针对CDK4/6减少YAP1稳定性的CRC的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症相关死亡的主要原因.
- 是-关联蛋白1 (YAP1) 失调促进了CRC中的癌症干和化学抵抗.
- 直接针对YAP1的策略受限于缺乏结合口袋和毒性.
研究的目的:
- 为了确定食品和药物管理局 (FDA) 批准的药物,可以针对结直肠癌中的YAP1.
- 阐明YAP1在CRC中受到调节的分子机制.
- 探索针对已确定途径的CRC的潜在治疗策略.
主要方法:
- 对FDA批准的药物的查,以检测CRC细胞中的YAP1向活性和患者衍生的异种移植模型.
- 使用生物化学测试,识别二维基因化酶3 (DUB3) 作为YAP1二维基因酶.
- 研究循环林依赖激酶4/6 (CDK4/6) 在调节DUB3和YAP1酸化和稳定性的作用.
- 在CRC标本中对DUB3和YAP1表达的组织学分析.
主要成果:
- 阿贝马西克利布是一种CDK4/6抑制剂,诱导YAP1的蛋白酶依赖性降解,抑制CRC的进展.
- DUB3被确定为对CRC中YAP1稳定负责的二基因酶.
- CDK4/6在Ser41中直接酸化DUB3,激活其对YAP1.1的二维基因酶活性.
- 在DUB3中抑制CDK4/6或Ser41突变导致YAP1降解和瘤进展的抑制.
- 在CRC标本中观察到DUB3和YAP1表达之间的正相关性.
结论:
- CDK4/6-DUB3通路促进YAP1稳定和结直肠癌中的瘤功能.
- 向CDK4/6代表了CRC患者的有希望的治疗策略,该患者的DUB3和YAP1.1水平升高.
- 这项研究揭示了YAP1调节的新机制,并为CRC提供了潜在的治疗途径.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
